Bleomycin stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activities.
Although bleomycin, an antineoplastic drug, is used in the treatment of a variety of tumors, the mechanisms of bleomycin-induced lung injury and fibrosis are not fully elucidated. We postulated that bleomycin might stimulate A549 cells, a type II pneumocyte cell line, to release neutrophil and monocyte chemotactic activities (NCA and MCA, respectively). To test this hypothesis, A549 cell supernatant fluids were harvested and evaluated for NCA and MCA. A549 cell supernatant fluids showed NCA and MCA in response to bleomycin in a dose- and time-dependent manner (P < 0.05). Checkerboard analysis revealed that both NCA and MCA were predominantly chemotactic. Partial characterization of the released NCA and MCA showed that the activities were partially heat labile, trypsin digested, and predominantly ethyl acetate extractable. Lipoxygenase inhibitors and cycloheximide inhibited the release of chemotactic activities significantly. Molecular-sieve column chromatography revealed that the released activities were heterogeneous. However, low-molecular-weight activity was prominent. Leukotriene B4-receptor antagonist, anti-interleukin-8, anti-granulocyte colony-stimulating factor, and anti-monocyte chemoattractant protein-1 antibodies attenuated the chemotactic activities. Immunoreactive leukotriene B4 receptor, interleukin-8, granulocyte colony-stimulating factor, and monocyte chemoattractant protein-1 significantly increased in supernatant fluids in response to bleomycin. These data demonstrate that bleomycin stimulates type II epithelial cells to release chemotactic activities and plays a role in inflammatory cell recruitment into the lung.
Sato
E
E
The First Department of Internal Medicine, Shinshu University, School of Medicine, Matsumoto 390, Japan.
Koyama
S
S
Masubuchi
T
T
Takamizawa
A
A
Kubo
K
K
Nagai
S
S
Izumi
T
T
D000963:Antimetabolites / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D002460:Cell Line; D002630:Chemotactic Factors / Q000378:metabolism*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D004815:Epidermal Growth Factor / Q000378:metabolism; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007975:Leukotriene B4 / Q000378:metabolism; D008168:Lung / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D018945:Monocyte Chemoattractant Proteins / Q000378:metabolism*; D009504:Neutrophils / Q000502:physiology*; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors
D000963:Antimetabolites; D000964:Antimetabolites, Antineoplastic; D002630:Chemotactic Factors; D016207:Cytokines; D018945:Monocyte Chemoattractant Proteins; D018102:Receptors, Leukotriene B4; D001761:Bleomycin; D007975:Leukotriene B4; D004815:Epidermal Growth Factor; D066246:ErbB Receptors